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CONTINUOUS TREATMENT WITH FIXED COMBINATION OF LABA/ICS
CAN AVOID COSTS OF HOSPITALIZATION IN ASTHMA AND COPD IN
GERMANY
Bonthapally V1, Sindern J2, Wolbring F2, Mehnert A3
1University of Louisiana at Monroe, Monroe, LA, USA, 2Janssen-Cilag GmbH, Neuss, 
Germany, 3Janssen-Cilag GmbH, Neuss, NRW, Germany
OBJECTIVES: To assess the impact of continuity of treatment on hospitalization rate
and costs of hospitalization in patients with asthma or COPD treated with ﬁ xed
combination (fc) of long-acting b2-agonists (LABA) and inhaled corticosteroids (ICS).
METHODS: For this retrospective analysis, German IMS Disease Analyzer with lon-
gitudinal electronic medical record was used to identify patients with at least one
diagnosis of asthma (ICD10 J45) or COPD (J44) in the study period October 2007–
September 2008, at least one fc-prescription in the ﬁ rst quarter of the study period
and physician visits in all four quarters. The population was subdivided by diagnosis 
(asthma and COPD) and by SHI status (pensioners and insured-persons/qualiﬁ ed-
family-member). Hospitalization rate was used as an indicator to assess the impact of 
continuity of treatment (continuous treatment (ct): at least one prescription of fc in
each quarter, non-continuous treatment (nct): at least one prescription of fc in 1–3 
quarters). Published data based on German DRGs were used to calculate hospitaliza-
tion costs. RESULTS: Of 106,911 patients with asthma or COPD, 2,486 insured-
persons/qualiﬁ ed-family-member and 1.692 pensioners met the inclusion criteria for
asthma; 801 insured-persons/qualiﬁ ed-family-member and 2,389 pensioners for 
COPD. In each of these subgroups, the proportion of patients with ct is signiﬁ cantly
(p  0.05, Wilcoxon) higher in patients without hospitalization compared to with 
hospitalization. The risk for hospitalization was increased 1.4 to 1.7-fold in patients
with nct (p  0.05) compared to patients with ct. The estimated associated additional
hospitalization costs for sick funds per 10,000 patients were 370,000–960,000 EUR/
year for the different subgroups of patients. CONCLUSIONS: There is a strong impact 
of continuity of treatment on hospitalization rate of patients with asthma or COPD.
Continuous treatment with ﬁ xed combination LABA/ICS can avoid asthma or COPD
related hospitalizations and therefore offers potential for cost savings.
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ADHERENCE AMONG COPD SUBJECTS ON TIOTROPIUM AND
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OBJECTIVES: Compare adherence, deﬁ ned as persistence and compliance, in subjects 
with chronic obstructive pulmonary disease (COPD) initiated on tiotropium bromide 
or ﬂ uticasone/salmeterol therapy. METHODS: This retrospective inception cohort
study used claims from a large national US health plan. Subjects with COPD were
selected for the study if they had q1 ﬁ ll of tiotropium or ﬂ uticasone/salmeterol between 
December 1, 2004 and December 31, 2005 and q12 (up to 18) months of continuous
enrollment. Persistence was deﬁ ned as days from the index prescription to the ﬁ rst 
60-day gap in the index drug. Subjects with a medication possession ratio (MPR)
q80% were “compliant” and MPR 80% were “non-compliant.” Persistence and 
compliance were modeled with Cox proportional hazard and logistic regressions, 
respectively. Covariates included index drug, demographics, baseline COPD severity,
and comorbidities. RESULTS: The sample comprised 1561 tiotropium and 2976 
ﬂ uticasone/salmeterol subjects. Seventy-eight percent of tiotropium subjects had a 
60-day gap in index therapy versus 89% of ﬂ uticasone/salmeterol subjects (p  0.001). 
tiotropium subjects were more compliant than ﬂ uticasone/salmeterol (20% vs. 9%, p 
 0.001). Mean length of persistence was 95.9 days for tiotropium vs. 77.3 for ﬂ uti-
casone/salmeterol (p  0.001). Cox regression showed that tiotropium subjects were
signiﬁ cantly more persistent with their index therapy than were ﬂ uticasone/salmeterol
subjects (hazard ratio for occurrence of 60-day gap: 0.72; conﬁ dence interval (CI):
0.67–0.77). Logistic regression results showed tiotropium subjects were signiﬁ cantly 
more likely to be compliant vs. ﬂ uticasone/salmeterol subjects (odds ratio: 2.25; CI: 
1.85–2.73). CONCLUSIONS: Tiotropium subjects were signiﬁ cantly more adherent
than ﬂ uticasone/salmeterol subjects. The results can have important implications for
management of COPD. Additional research in different COPD populations should be
undertaken to investigate these ﬁ ndings further.
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MEDICATION USE AND ASTHMA CONTROL – ANALYZING ECONOMIC
TRADEOFFS USING INSURANCE CLAIMS DATA
Saha S, Nurmagambetov T
Centers for Disease Control and Prevention, Atlanta, GA, USA
Recommended care (Expert Panel Report 3, NAEPP 2007)) for severe asthma patients 
may entail expenditure on controller medications that could lead to nonadherence
to prescription asthma medications. Consequently, nonadherence may increase the
likelihood of asthma exacerbations that could increase long term health care cost. 
OBJECTIVES: This paper examines if nonadherence to controller medications 
increases total health care expenditure for severe asthma patients over time due to
increased frequency of severe exacerbations. METHODS: Insurance claims from the 
Marketscan database were used to select continuously-enrolled individuals who had
inpatient admissions or emergency room visits in 2005 with asthma as the principal 
diagnosis. These individuals, considered to suffer from severe asthma, were followed 
through the end of 2006 to assess the impact of medication use on the recurrence of 
severe asthma exacerbations (i.e., repeat hospitalization or emergency department 
visit) and subsequent increased medical expenditure. For every individual, the 
American Lung Association classiﬁ cation of asthma medication was used to classify 
prescription medications into controller and reliever categories. RESULTS: 1) Ten 
percent of the sample in 2005 had an exacerbation in 2006. Results from a Probit 
model with selection indicated that individuals using less controller medication were 
more likely to experience a recurrence of asthma exacerbation, and 2) Results from
the two-part and Heckman selection models indicated that increase in use of controller
medications was associated with increased expenditure on prescription medications 
but lower hospitalization and emergency visit expenditure due to exacerbations. 
CONCLUSIONS: The cross-sectional nature of the data precludes inferences about 
causality between medication use and asthma-related expenditures. However, the
ﬁ nancial tradeoffs (between prescription drugs payments and possible exacerbation-
related expenditure) facing asthma patients have implications for adherence to pre-
scribed medications and effectiveness of long-term asthma control. More research is 
required to examine how modiﬁ cations in insurance payments can improve adherence 
to asthma medications.
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OBJECTIVES: To examine appropriateness of initiation of ICS/LABA combination 
therapy, according to US National Heart, Lung and Blood Institute guidelines, among
asthma patients. METHODS: A retrospective cohort study of asthma patients (aged
12–64 years) from the PHARMetrics database who initiated ﬂ uticasone salmeterol 
combination (FSC) or budesonide formoterol combination (BFC) therapy from 
7/1/2007–6/30/2008 was conducted. Index date was deﬁ ned as ﬁ rst ICS/LABA com-
bination medication claim during this time period. Patients were excluded if they had
used ICS/LABA combination medication and/or were not continuously enrolled during 
the year before the index date (pre-index period) or had a COPD diagnosis. Medical
and pharmacy utilization was examined for the pre-index period. ICS/LABA combina-
tion therapy use was considered appropriate if within the pre-index period patients 
had any of the following criteria: controller medication (ICS or leukotriene receptor 
antagonist [LTRA]) use; asthma-related emergency room (ER) visit or hospital admis-
sion, 2 bursts of oral systemic corticosteroids; or 6 short-acting B-agonist (SABA) 
canisters. Factors associated with appropriate ICS/LABA combination therapy use 
were assessed by multivariate logistic regression. RESULTS: Of 16,205 patients who
initiated ICS/LABA combination therapy, 1,417 had BFC and 14,788 had FSC. Among 
these patients, 55.6% of BFC patients compared with 37.9% of FSC patients met all 
of the criteria for appropriate use. Prior controller medication use was signiﬁ cantly 
higher for BFC than FSC patients (45.7% vs. 26.1%; P  0.001), and prior ICS medi-
cation use comprised most of the difference (31.1% vs. 11.0%; P  0.001). BFC users
were more likely than FSC users to meet all of these criteria (odds ratio, 1.74; 95% 
CI, 1.59–2.00; P  0.001) after controlling for other factors including age, gender, 
region, comorbidities, and prescriber specialty. CONCLUSIONS: A signiﬁ cantly 
greater proportion of BFC than FSC users were appropriate for ICS/LABA combina-
tion therapy based on prior controller medication use or high-risk criteria. Supported 
by AstraZeneca LP.
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OBJECTIVES: Objective of this analysis was to evaluate the current usage of ﬁ xed 
and free combinations of long-acting b2-agonists (LABA) and inhaled corticosteroids
(ICS) using real-life electronic medical record data. METHODS: In a retrospective
data analysis using Germany IMS disease analyzer with longitudinal medical records 
for the period October 2007-September 2008, patient records were extracted. Patients 
had to have at least one diagnosis of asthma(ICD10-J45) and at least one GP visit in 
each quarter of the study period and at least one prescription of LABA (formoterol 
or salmeterol) or ﬁ xed combination (ATC R3F) in the ﬁ rst quarter of the study period
to make sure patients had chronic asthma. LABA-treated patients were analyzed by 
number of quarters with concomitant treatment of ICS. Hospitalization rate was 
considered as indicator to assess treatment outcomes. RESULTS: Of 3969 patients 
receiving at least one prescription of ﬁ xed combination, 40.3% received continuous
treatment (i.e. at least one prescription per quarter). In total 1124 patients had at least
one single-agent LABA prescription in the study period, 42.9% of these received con-
tinuous LABA-treatment while 12.1% received continuous LABA  ICS treatment. 
Continuous treatment with free combination of ICS and LABA was associated with
a signiﬁ cantly lower risk of hospitalization compared to non-continuous treatment of 
free combination (p  0.01; Fisher’s Exact). Of patients continuously treated with 
LABA, 32.8% did not receive any ICS prescription in the study period. CONCLU-
SIONS: Continuous treatment with free combination was much less frequent than
with ﬁ xed combinations. In contrast to general asthma treatment guidelines and drugs’ 
labels of LABA, a signiﬁ cant proportion of patients received only LABA and no ICS.
The results of this analysis were in line with the FDA’s expert panel’s concerns of 
potentially inappropriate use of LABA in asthma treatment.
